What Are Wall Street Analysts' Target Price for AbbVie Stock?

With a market cap of $443.4 billion, AbbVie Inc. (ABBV) is a biopharmaceutical company focused on discovering and delivering innovative medicines and solutions to address serious health conditions and unmet medical needs. Its key therapeutic areas include immunology, neuroscience, and oncology, along with products and services offered through its Allergan Aesthetics portfolio.

Shares of the drugmaker have slightly outperformed the broader market over the past 52 weeks. ABBV stock has soared 25.8% over this time frame, while the broader S&P 500 Index ($SPX) has increased 21.5%. However, shares of the company are up 7.5% on a YTD basis, slightly lagging behind SPX’s 10.7% rise.